{"props":{"pageProps":{"profile":{"ipoDate":"2013-09-18","search":["x","xl","xlr","xlrn","a","ac","acc","acce","accel","accele","acceler","accelero","acceleron","acceleron ","acceleron p","acceleron ph","acceleron pha","acceleron phar","acceleron pharm","acceleron pharma","acceleron pharma ","acceleron pharma i","acceleron pharma in","acceleron pharma inc","acceleron pharma inc."],"exchangeShort":"NASDAQ","industry":"Biotechnology","sector":"Healthcare","description":"Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.","website":"http://www.acceleronpharma.com","isStatic":true,"currency":"USD","symbol":"XLRN","name":"Acceleron Pharma Inc."}},"__N_SSG":true},"page":"/quote/[symbol]","query":{"symbol":"XLRN"},"buildId":"Njk4sJo_1dBWR55wHuASm","isFallback":false,"gsp":true,"scriptLoader":[]}